INTRODUCTION
The atypical antipsychotics which are associated with a substantially lower liability for extrapyramidal side effects and reduced risk of tardive dyskinesia provide major advance in the pharmacotherapy of schizophrenia when compared with the typical agents (1) . In contrast they are found to be related with some important adverse effects including hyperprolactinemia (which may result with gynecomastia, galactorrhea, amenorrhea, sexual dysfunction, and lowered bone mineral density), weight gain, higher risk for diabetes mellitus and prolongation of the corrected QT interval. These adverse effects may provoke the treatment non-adherence in schizophrenia patients (2) . The paliperidone palmitate, one of the effective atypical antipsychotic in schizophrenia, has D2 and 5HT2A receptor antagonism effects that is similar to risperidone. Although, the risperidone has a high affinity for 5-HT2A receptor, it increases prolactin levels like typical antipsychotics. Additionally hyperprolactinemia was also reported after paliperidone palmitate injection3. On the other hand, previous studies indicated that aripiprazole has potent partial agonist activity at D2 and 5-HT1A receptors and antagonist activity at 5-HT2A receptors (4). Since its pharmacological profile differs from other atypical agents, it is considered that aripipirazole causes lesser extrapyramidal symptoms, glucose intolerance, weight gain, and hyperprolactinemia side effects (5) . In this context, there were many reports regarding the utility of aripiprazole in elevated serum prolactin levels in schizophrenia patients (6) . Now aripiprazole once monthly 
CASE PRESENTATION
A 37-year-old woman, who has been receiving paliperidone palmitate 100 mg/month, presented to our psychiatry outpatient clinic. According to her family, she was hospitalized with the diagnosis of schizophrenia 2 years ago. During her hospitalization she had been using risperidone 6 mg/day and after her psychotic symptoms improved she was discharged from the clinic with the same treatment regimen. After 2 months from discharge she discontinued oral risperidone and then her psychiatrist started paliperidone palmitate 100 mg/month immediately.
Her psychotic symptoms did not occur again while she has been undergoing injectable treatment. When we first met with the patient, she had still been receiving her monthly injections of paliperidone palmitate and her PANSS score 
DISCUSSION
In our case hyperprolactinemia occurred due to paliperidone palmitate injection and we reported the decrease in prolactin levels after switching the treatment to the aripiprazole LAI. In the literature, some reports stated that oral aripiprazole addition lowers prolactin levels in hyperprolactinemia cases with the use of both oral and injectable paliperidone (9) . If the patient provides benefit from the antipsychotic treatment, it is suggested that adding oral aripiprazole to the treatment may be better option (10) . In our case, we added oral aripiprazole according to the literature but weak oral treatment adherence caused sustained hyperprolactinemia, despite we had lowered the paliperidone palmitate dosage from 100 mg to 75 mg/mont. In order to avoid recurrence, her medication was switched to the aripirazole LAI. According to prescribing information, in conjunction with first dose of LAI, the patient should take 14 consecutive days of concurrent oral aripiprazole but additionally there is not any information including switching from paliperidone palmitate, hence we waited for the injection cycle and hospitalized the patient for oral treatment adherence. The serum prolactin levels remained between normal ranges for 7 months with aripiprazole LAI. Hyperprolactinemia impaired treatment compliance of our patient therefore specifically young female patients should be monitored closely regarding these adverse events. To the best of our
